Work

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.3099.3099

Authors: Beth Christian, Lai Wei, Jennifer Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina Wagner-Johnston, Nancy L. Bartlett, Kristie A. Blum

Institutions: The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Washington University in St. Louis, Alvin J. Siteman Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4239154874

FWCI: 0.219

Cites:

Cited by: 4

Related to: 10